| Description |
- A Phase 2/3 trial evaluating Dupilumab in eosinophilic gastritis (EoG), with or without eosinophilic duodenitis (EoD), demonstrated significant reductions in gastric and duodenal eosinophil counts and improvement in symptom scores. As no FDA-approved treatments currently exist for these eosinophilic gastrointestinal diseases (EGIDs), Dupilumab may offer a targeted, disease-modifying option. These findings support the potential of IL-4/IL-13 inhibition as a first-in-class therapy and a promising advance in the management of EGIDs.
|
|---|